- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.03. | Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target | ||
| 28.03. | Eli Lilly's Alzheimer's contender Kisunla gets thumbs down from EU regulators over safety concerns | ||
| 28.03. | AstraZeneca, Sanofi, Lilly, Pfizer CEOs meet with Xi Jinping amid US-China trade tensions | ||
| 28.03. | Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M | ||
| 28.03. | Moderna brand chief Kate Cronin leaves for 'next chapter' | ||
| 28.03. | Senate investigation claims Pfizer shifted profits offshore in what could be pharma's 'largest tax-dodging scheme' | ||
| 28.03. | Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians | ||
| 28.03. | Fierce Pharma Asia-Novo's triple G obesity bet; Merck's latest China deal; Hengrui, Elevar's 2nd FDA snub | ||
| 28.03. | Manufacturing issues trip up Milestone's long-awaited FDA landmark | ||
| 27.03. | Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR | ||
| 27.03. | GSK tip claiming Pfizer delayed COVID vaccine results during 2020 election prompts US probe: WSJ | ||
| 27.03. | Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme | ||
| 27.03. | Chiesi lays out €430M to revitalize Italian production site for inhaler, biologics manufacturing | ||
| 27.03. | Lilly adds Alzheimer's disease care to DTC telehealth platform | ||
| 26.03. | Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey | ||
| 26.03. | Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts | ||
| 26.03. | FDA calls out 'particularly concerning' claims on HCP site for Taiho's Lytgobi | ||
| 26.03. | India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems | ||
| 26.03. | ATyr hires ex-ChemoCentryx commercial chief for planned launch | ||
| 26.03. | To approve Exelixis' Cabometyx in neuroendocrine tumors, FDA recognizes 'crossover impact' on survival | ||
| 26.03. | Roche's Ocrevus, Novartis' Kesimpta set to lead CNS market to strongest growth in over a decade: report | ||
| 26.03. | Senate confirms Johns Hopkins surgeon Marty Makary to lead FDA amid turbulence at the agency | ||
| 25.03. | GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa | ||
| 25.03. | Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to 'string of recent wins' | ||
| 25.03. | Eisai lays out road map to blockbuster sales projections for Leqembi's 'milestone' 2027 year |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
